This drug is a small molecule inhibitor of PHD1/2 designed to treat anemia of chronic kidney disease (CKD). PHD1/2 inhibition can upregulate the expression of several iron metabolism genes and address both impaired EPO production and functional iron deficiency, common in anemia of CKD. The drug aims to enhance EPO secretion, stimulating red blood cell production and potentially ameliorating anemia.
×
Insilico Medicine � PHD1/2 Inhibitor (Anemia of CKD treatment)
© 2021 - Lifespan Extension Advocacy Foundation - LIFESPAN2023
The opinions expressed in interviews or commentary in articles appearing on this site are those of the subject or subjects and do not necessarily reflect the views of LEAF/Lifespan.io, its directors, officers or employees.
Powered by MMD